GCP
DGX icon

Gill Capital Partners’s Quest Diagnostics DGX Stock Holding History

Gill Capital Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.8K Buy
+50
New +$9.71K ﹤0.01% 448

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Gill Capital Partners's DGX Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Quest Diagnostics (DGX) in Q1 2026: 50 shares worth $9.8K. The stake represents ﹤0.01% of the portfolio and ranks #448 among its holdings.

1,067 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Gill Capital Partners held 50 shares of Quest Diagnostics worth $9.8K as of Q1 2026.
  • Quest Diagnostics was a new Gill Capital Partners position in Q1 2026.
  • Quest Diagnostics made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #448 holding.
  • 1,067 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.